The molecule that could alleviate stroke-related brain injury
Science Daily - Stroke
JULY 10, 2024
New research identifies novel path to protecting the brain from stroke-induced damage.
Wed.Jul 10, 2024
117 
Study Calls for Targeted Strategies for Managing Diabetic Cardiomyopathy Across Racial, Ethnic Groups
DAIC
JULY 10, 2024
Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal of the American College of Cardiology, JACC, shed light on the racial and ethnic disparities in diabetic cardiomyopathy (DbCM), which researchers note may have the potential to inform clinical practice, interventions, and policies. Image courtesy: Getty Images christine.book Wed, 07/10/2024 - 12:02 July 10, 2024 — Findings from an observational analysis of ARISE-HF trial participants, newly-pub
Molecular atlas of blood vessel pathways in the human brain, across early brain development, adulthood and disease
Science Daily - Stroke
JULY 10, 2024
Researchers have built the first-ever molecular atlas of the human brain vasculature at single-cell resolution, spanning from early development to adulthood and through disease stages such as brain tumors and brain vascular malformations.
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
DAIC
JULY 10, 2024
Getty Images mtaschetta-millane Wed, 07/10/2024 - 08:51 July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc. , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced European Patent EP3244896 has been granted by the European Patent Office (EPO) covering use of brilaroxazine for the treatment of PH, adding to its existing patent protection in key ma
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
A diagnostically challenging case of wide complex tachycardia
Heart BMJ
JULY 10, 2024
Clinical introduction A woman in her 60s with non-obstructive coronary artery disease, aortic valve replacement and aortic arch repair, chronic diastolic heart failure and paroxysmal atrial fibrillation (AF) and flutter (AFL), presented with 3 days of sustained palpitations that felt similar to prior episodes of AF/AFL. She was euvolemic, haemodynamically stable, with a regular rhythm.
Step Into the Cardiology Clinic of the Future: Bringing Virtual Cardiac Care Delivery and Virtual Telemetry to Life in Your Practice’s Clinical Workflows
DAIC
JULY 10, 2024
In a room of 20 people, it’s likely that about 10 of them, or half, will presently have some form of cardiovascular disease (CVD). CVD is among the most prevalent diseases in the U.S., and strokes and other CVDs are on the rise globally. One report projects a 50% increase in stroke-related deaths by 2050, with 10 million dying annually. Atrial fibrillation (AFib) cases have also surged, doubling from 28.3 million in 1990 to 56.7 million in 2019.
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction
DAIC
JULY 10, 2024
mtaschetta-millane Wed, 07/10/2024 - 09:02 July 10, 2024 — CellProthera , a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera , as well as plans to continue the relationship into Pha
Sarcopenia and aortic valve disease
Heart BMJ
JULY 10, 2024
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR). Despite improvements in outcomes, older adults with competing comorbidities and geriatric syndromes have suboptimal quality of life outcomes, highlighting the cumulative vulnerability that persists despite val
Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and Diabetic Macular Edema
HCPLive
JULY 10, 2024
A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.
Sleep apnea sufferers more likely to develop heart disease, study finds
Medical Xpress - Cardiology
JULY 10, 2024
Obstructive sleep apnea (OSA) is linked to an increased risk of cardiovascular disease in adults, even those younger than 40, researchers at UT Southwestern Medical Center found.
Raj Chovatiya, MD, PhD: Discussing the FDA Approval of Roflumilast for Atopic Dermatitis
HCPLive
JULY 10, 2024
In this interview, Chovatiya discussed the recent FDA approval of roflumilast cream 0.15% for patients with eczema aged 6 years and older.
Routine ECG screening may help to prevent cardiovascular disease events in adults
Medical Xpress - Cardiology
JULY 10, 2024
Routine electrocardiogram (ECG) screening may help to prevent cardiovascular disease (CVD) events, according to a study published online July 1 in JAMA Internal Medicine.
Gerd Burmester, MD: Long-Term Data Supports Upadacitinib's Safety in Rheumatic Disease Treatment
HCPLive
JULY 10, 2024
Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.
The cardiologists who get the best, worst online reviews
Becker's Hospital Review - Cardiology
JULY 10, 2024
Female and older cardiologists receive lower average ratings in online reviews compared to other cardiologists, a recent study found.
Nearly Half of American Counties Don’t Have Cardiologists
CardiacWire
JULY 10, 2024
If it seems like your patients are coming from a lot further away these days, that might because nearly half of U.S. counties don’t have a single cardiologist working there. Researchers from Brigham and Women’s Hospital teamed up with GoodRx to analyze data from all 3,143 counties in the US, finding that 46.3% of U.S. counties don’t have a single cardiologist, and this regional cardiologist imbalance often results in… Much Longer Patient Drives – The 22M people who live in these “car
Women over 65 face higher heart surgery risks at low-quality hospitals
Becker's Hospital Review - Cardiology
JULY 10, 2024
Women age 65 or older who underwent coronary artery bypass grafting, have a higher mortality rate than men and are more likely to be treated at "low-quality hospitals", according to a national study led by researchers from the University of Michigan and published July 10 in JAMA Network Open.
Atherosclerotic cardiovascular disease risk prediction: current state-of-the-art
Heart BMJ
JULY 10, 2024
Learning objectives Understand atherosclerotic cardiovascular disease (ASCVD) risk scores and how and when to use them. Appreciate the differences among the major risk assessment models and select the best tool for each patient. Identify traditional and newer risk factors associated with ASCVD. Appreciate the future of large-model risk prediction calculators and individualised decision-making tools.
Women over 65 face higher mortality rates at low quality hospitals after heart surgery
Medical Xpress - Cardiology
JULY 10, 2024
Women over the age of 65 who require complex heart surgery are more likely than men to receive care at low quality hospitals—where they also die in greater numbers following the procedure, a Michigan Medicine study finds.
CMS Releases Proposed 2025 Medicare Physician Fee Schedule and Hospital OPPS Rule
American College of Cardiology
JULY 10, 2024
The Centers for Medicare and Medicaid Services (CMS) has released the proposed 2025 Medicare Physician Fee Schedule (PFS). Of note, the PFS conversion factor has been updated from $33.2875 to $32.3562, a 2.80% cut. The overall reimbursement for cardiovascular services is projected to remain flat compared with 2024, with changes to policies and individual services roughly balancing out.
Researchers elucidate mechanism behind cardiac fibrosis, opening way for new heart failure treatments
Science Daily - Heart Disease
JULY 10, 2024
Cardiovascular disease often culminates in heart failure, a hallmark of which is fibrosis, a form of tissue scarring. Cardiac fibrosis initially repairs damaged heart tissue, but it can quickly become excessive and pathological. Identifying the mechanisms behind fibrosis is a focal point in cardiovascular research, and now scientists discovered a critical genetic mechanism driving the process -- and they have identified a target for reversing it.
Iron Repletion and HF, Ventricular Septal Defect and Acute MI, Hemodynamic Assessment for HF
American College of Cardiology
JULY 10, 2024
In this week’s View, Dr. Eagle discusses a state-of-the-art review on iron repletion for patients with heart failure and iron deficiency.
Diuretics for Ambulatory HF Patients With Volume Overload: Winners & Losers
Med Page Today
JULY 10, 2024
(MedPage Today) -- For patients with chronic heart failure (HF) who have persistent congestion despite high doses of oral loop diuretics, the right way to intensify diuretics in the outpatient setting may be narrowed, based on a small randomized.
Percutaneous Coronary Revascularization Strategies After MI
American College of Cardiology
JULY 10, 2024
What is the outcome of contemporary revascularization strategies in patients presenting with myocardial infarction (MI) and multivessel coronary artery disease (CAD)?
Anti-VEGF Prior Authorizations Often Delay Care in Retina Practices
HCPLive
JULY 10, 2024
Prior authorizations for the anti-VEGF therapies aflibercept, ranibizumab, and bevacizumab were almost always approved but delayed care for most patients.
Women lose more years of life after a heart attack than men, research finds
Medical Xpress - Cardiology
JULY 10, 2024
A new study shows that women lose more years of life after a heart attack than men. A 50-year-old woman with a large heart attack loses an average of 11 years, while an 80-year-old man with a small heart attack loses an average of 5 months of life. The study was led by researchers at Karolinska Institutet and Danderyd Hospital and the results have been published in the journal Circulation.
Despite Similar Treatment Effects, Women with FH Less Likely to Receive Treatment or Meet Goals
HCPLive
JULY 10, 2024
Study finds women with familial hypercholesterolemia receive less intensive treatment and are less likely to achieve LDL-C goals than men.
Large-Scale Proteomics and Hypertensive Disorders of Pregnancy
American College of Cardiology
JULY 10, 2024
Can proteome assessment of first-trimester blood samples be used to predict the development of hypertensive disorders of pregnancy (HDP)?
Benefits of Hepatocellular Carcinoma Screening Continue After HCV Cure, Study Finds
HCPLive
JULY 10, 2024
Findings underscore the importance of HCC screening adherence in patients with HCV-related cirrhosis who achieve HCV cure for improving overall survival.
Frozen Frontiers: Understanding Cardiovascular Dynamics in Winter Sport Athletes
American College of Cardiology
JULY 10, 2024
Interest and research in exercise science is growing, though winter sports are underrepresented. Much of the existing research on winter sports is focused on injuries.
Nearly Half of US Counties Lack Practicing Cardiologists
HCPLive
JULY 10, 2024
Approximately 1454 counties with 2 million residents have no cardiologist in the US, primarily affecting rural and socioeconomically disadvantaged areas.
Association between triglyceride glucose-waist height ratio index and cardiovascular disease in middle-aged and older Chinese individuals: a nationwide cohort study
Cardiovascular Diabetology
JULY 10, 2024
The triglyceride-glucose (TyG) index and its combination with obesity indicators can predict cardiovascular diseases (CVD). However, there is limited research on the relationship between changes in the triglyc.
SEQUOIA: Fazirsiran Reduces Serum, Liver Z-AAT Concentrations, Improves Hepatic Globule Burden
HCPLive
JULY 10, 2024
Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
Cardiovascular Diabetology
JULY 10, 2024
Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T2D) and cardiovascular disease [mostly atherosclerotic (ASCVD)] were randomized to empagliflozin or placebo and followed for a median 3.1 years.
Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells
Frontiers in Cardiovascular Medicine
JULY 10, 2024
Cardiotoxicity can be defined as “chemically induced heart disease”, which can occur with many different drug classes treating a range of diseases. It is the primary cause of drug attrition during pre-clinical development and withdrawal from the market. Drug induced cardiovascular toxicity can result from both functional effects with alteration of the contractile and electrical regulation in the heart and structural changes with morphological changes to cardiomyocytes and other cardiac cells.
Clinical Quiz: Active Oligoarthritis Treatment Recommendations from 2021 ACR JIA Guidelines
HCPLive
JULY 10, 2024
Test your knowledge of active oligoarthritis treatment recommendations from the 2021 ACR guideline on JIA with this quiz.
Case Report: Mechanical hemolysis resulting from left ventricular outflow tract obstruction after aortic valve replacement relieved by transapical beating-heart septal myectomy
Frontiers in Cardiovascular Medicine
JULY 10, 2024
BackgroundAortic stenosis (AS) in combination with left ventricular outflow tract obstruction (LVOTO) has occasionally been reported. However, making a precise diagnosis and successfully treating this combination is challenging due to the hemodynamic interaction between the two conditions.Case summaryA 56-year-old male patient who had been diagnosed with severe AS and asymmetric left ventricular hypertrophy underwent aortic valve replacement (AVR) and a conventional septal myectomy.
Let's personalize your content